EODData

MEMBERSHIP REGISTER LOG IN

FRA, S49: Supernus Pharmaceuticals Inc

02 Oct 2025
LAST:

40.80

CHANGE:
 0.60		OPEN:
40.80		HIGH:
40.80		ASK:
0.00		VOLUME:
62
CHG(%):
1.49		PREV:
40.20		LOW:
40.80		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
02 Oct 2540.8040.8040.8040.8062
01 Oct 2540.2040.2040.2040.200
30 Sep 2540.4040.4040.4040.400
29 Sep 2540.2040.2040.2040.2062
26 Sep 2540.2040.2040.2040.2062
25 Sep 2540.0040.0040.0040.0062
24 Sep 2539.6039.6039.6039.6062
23 Sep 2539.6039.6039.6039.6062
22 Sep 2539.0039.0039.0039.0062
19 Sep 2539.0039.0039.0039.0062

COMPANY PROFILE

Name:Supernus Pharmaceuticals Inc
About:Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Sector:Healthcare
Address:9715 Key West Avenue, Rockville, MD, United States, 20850
Website:https://www.supernus.com
ISIN:US8684591089
LEI:549300GRM36VBKISYJ58

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:38.78
Price to Book:2.38
Price to Sales:3.20
EBITDA:132.22M
Shares:56.07M
Market Cap:2.288B

TECHNICAL INDICATORS

MA5:40.36
MA10:39.90
MA20:39.26
MA50:36.65
MA100:32.34
MA200:32.24
STO9:100.00
STO14:100.00
RSI14:58.82
MTM14:2.20
ROC14:0.06
ATR:0.49
Week High:40.80
Week Low:40.00
Month High:40.80
Month Low:37.00
Year High:40.80
Year Low:26.26
Volatility:21.19